Trials / Completed
CompletedNCT00698516
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
An Open-label, Multicenter, Non-comparative, Phase II Study of Oral Topotecan in Combination With Bevacizumab for Second-line Treatment in Subjects With Relapsed Small-cell Lung Cancer (SCLC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab) | 2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle. |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2008-06-17
- Last updated
- 2012-03-27
- Results posted
- 2011-02-03
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00698516. Inclusion in this directory is not an endorsement.